I. Medina

Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi‐centre, double‐blind, randomized, placebo‐controlled study

T. Zuberbier, I. Jáuregui, R. Valiente, 2010, Allergy.

Update on Omalizumab for Urticaria: What’s New in the Literature from Mechanisms to Clinic

D. Larenas-Linnemann, C. Parisi, Elizabeth García, 2018, Current Allergy and Asthma Reports.

The global impact of the COVID‐19 pandemic on the management and course of chronic urticaria

T. Zuberbier, M. Rudenko, J. Bernstein, 2020, Allergy.

The global burden of chronic urticaria for the patient and society *

J. Bernstein, M. Gonçalo, M. Ben-Shoshan, 2020, The British journal of dermatology.

Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study.

L. Dubertret, E. Arnáiz, I. Izquierdo, 2007, European journal of dermatology : EJD.

Effects of pregnancy on chronic urticaria: Results of the PREG‐CU UCARE study

M. Rudenko, M. Al-Ahmad, M. Maurer, 2021, Allergy.

Definition, aims, and implementation of GA2LEN/HAEi Angioedema Centers of Reference and Excellence

Todor A Popov, T. Zuberbier, N. Papadopoulos, 2020, Allergy.

Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria : a multi-centre , double-blind , random-ized , placebo-controlled study

T. Zuberbier, I. Jáuregui, R. Valiente, 2010 .

Treatment patterns and outcomes in patients with chronic urticaria during pregnancy: Results of PREG‐CU, a UCARE study

M. Rudenko, Zuotao Zhao, M. Maurer, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.